Till startsida
University of Gothenburg
To content Read more about how we use cookies on gu.se


The overall objective is to develop a novel preventative intervention for the blinding disease retinopathy of prematurity (ROP) and other complications of prematurity. This work is based on the concept that replacement of critical factor(s), normally provided in utero and reduced due to the disruption of the maternal/fetal interaction, to the infant born prematurely will help prevent the complications of premature birth.

We have shown experimentally and clinically that low IGF-I levels in premature infants strongly correlate with ROP development, indicating that IGF-I is one of these critical factors. Our preliminary work suggests that replacement of IGF-I to normal levels found in utero will prevent ROP and other complications of premature birth.

If successful, this will result in a clinical availability of a new orphan designated drug product, Premiplex®, improved care of preterm infants and a significant contribution towards the goal of the International Rare Disease Research Consortium (IRDiRC) by delivering one new therapy for the rare disease ROP.

Contact Information

Chatarina Löfqvist, Project Manager

Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, The Queen Silvia Children's Hospital, SE-416 85 Gothenburg, SWEDEN

+46 76 867 2719

+46 31 84 89 52

Page Manager: Carola Pfeiffer Mosesson|Last update: 3/28/2013

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?